At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 272 enrolled
Drug / intervention
OLAPARIBdrug
Likely dose
OLAPARIB 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
In Brief
A Phase 2 clinical trial evaluating OLAPARIB for Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity. Completed, enrolled 272 participants across 47 sites in 2 countries.
Detailed Summary
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedDec 6, 2016
Enrollment StartDec 22, 2016
Primary CompletionDec 3, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.6 years ago
Interventions
OLAPARIBdrug
300 mg olaparib tablets taken orally twice daily